

DESCRIPTION

Source *E. coli*-derived zebrafish FGF basic/FGF2/bFGF protein
Accession # AAI62367.1

Predicted Molecular Mass 17 kDa

SPECIFICATIONS

SDS-PAGE Monomeric zebrafish FGF-2 (bFGF) protein only

Activity No significant difference between EC₅₀ of reference and test lots

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Mass Spectrometry Single species with expected mass

Mycoplasma Negative when tested in both ribosomal RNA hybridization and luminescence assays

Formulation Lyophilized from Tris/NaCl/Cys/mannitol See Certificate of Analysis for details.

PREPARATION AND STORAGE


Reconstitution Resuspend in water at >100 µg/ml, prepare single use aliquots, add carrier protein if desired.

Shipping The product is shipped lyophilized at ambient temperature, on ice blocks or dry ice. Shipping at ambient temperature does not affect the bioactivity or stability of the protein. Upon receipt, store immediately at the conditions stated below.

Stability & Storage BulkLotPrefix assignment required for Storage Info


DATA

Bioactivity



Recombinant Zebrafish FGF-2 (bFGF), Animal-Free Protein Bioactivity Zebrafish FGF2 activity is determined using the Promega serum response element luciferase reporter assay (*) in transfected HEK293T cells. Cells are treated in triplicate with a serial dilution of FGF2 for 6 hours. Firefly luciferase activity is measured and normalized to the control Renilla luciferase activity. EC₅₀ = 0.42 ng/ml (24.7 pM).
*Promega pGL4.33[luc2P/SRE/Hygro] #E1340

SDS-PAGE



Recombinant Zebrafish FGF-2 (bFGF), Animal-Free Protein SDS-PAGE FGF2 migrates as major band at 17 kDa in non-reducing (-βME) conditions and upon reduction (+βME). The higher molecular mass band at 35 kDa is a dimer that we always see in our highly purified zebrafish FGF2 protein, the presence of this does not affect biological activity. Purified recombinant protein (7 µg) was resolved using 15% w/v SDS-PAGE in reduced (+β-mercaptoethanol, R) and non-reduced conditions (NR) and stained with Coomassie Brilliant Blue R250.

BACKGROUND

FGF basic (also known as FGF-2 and HBGF-2) is an 18-34 kDa, heparin-binding member of the FGF superfamily of molecules (1-3). Superfamily members are characterized by the presence of a centrally placed β -trefoil structure. FGF acidic (FGF-1) and FGF basic (FGF-2) were the first two identified FGFs, and the designations acidic and basic refer to their relative isoelectric points. Human FGF basic is 288 amino acids (aa) in length. There are multiple start sites, four of which utilize atypical CUG codons, and one that initiates at an AUG start site (4-6). The four CUG start sites generate high molecular weight (HMW) FGF basic. There is a 34 kDa, 288 aa form, a 24 kDa, 210 aa form, a 22.5 kDa, 201 aa form, and a 22 kDa, 196 aa form. All are retained intracellularly, undergo extensive methylation, and possess one or more nuclear localization signals (NLS) (7-9). The AUG initiating form is 18 kDa and 155 aa in length. There is no signal sequence (ss). It is, however, secreted directly through the plasma membrane via a mechanism that appears to be dependent upon tertiary structure (10). In place of a ss, there is purportedly a 9 aa N-terminal prosegment that precedes a 146 aa mature segment (11). Early isolations of 18 kDa bovine FGF basic yielded 146 aa molecules, an effect attributed to the presence of acid proteases (12). The molecule contains a heparin-binding site (aa residues 128-144), and undergoes phosphorylation at Ser117 (13). There is also an ill-defined C-terminal NLS that may be more "functional" (or 3-dimensional) than structural (7). Human 146 aa FGF basic is 97% aa identical to mouse FGF basic (14).

References:

1. Sorenson, V. *et al.* (2006) *BioEssays* **28**:504.
2. Kardami, E. *et al.* (2004) *Cardiovasc. Res.* **63**:458.
3. Nugent, M.A. and R.V. Lozzo (2000) *Int. J. Biochem. Cell Biol.* **32**:115.
4. Abraham, J.A. *et al.* (1986) *EMBO J.* **5**:2523.
5. Prats, H. *et al.* (1989) *Proc. Natl. Acad. Sci. USA* **86**:1836.
6. Arnaud, E. *et al.* (1999) *Mol. Cell. Biol.* **19**:505.
7. Foletti, A. *et al.* (2003) *Cell. Mol. Life Sci.* **60**:2254.
8. Arese, M. *et al.* (1999) *Mol. Biol. Cell* **10**:1429.
9. Pintucci, G. *et al.* (1996) *Mol. Biol. Cell* **7**:1249.
10. Nickel, W. (2005) *Traffic* **6**:607.
11. SwissProt # P09038.
12. Klagsbrun, M. *et al.* (1987) *Proc. Natl. Acad. Sci. USA* **84**:1839.
13. Bailly, K. *et al.* (2000) *FASEB J.* **14**:333.
14. Hebert, J.M. *et al.* (1990) *Dev. Biol.* **138**:454.

PRODUCT SPECIFIC NOTICES

The above product was manufactured, tested and released by R&D System's contract manufacturer, Qkine Ltd, at 1 Murdoch House, Cambridge, UK, CB5 8HW. The product is for research use only and not for the diagnostic or therapeutic use.